All In Biotech

Drug Trial Radar · NCT04807881

Phase Ib Clinical Study of Keynatinib

An Exploratory Clinical Study of Keynatinib in Relapsed/Refractory B-cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Sep 24, 2020

Primary completion

Oct 10, 2032

Study completion Apr 10, 2033

Sponsor

Lead sponsor
Medolution Ltd.Industry
Sponsor type
Industry
First posted
Mar 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety, PK characteristics in subjects with relapsed/refractory B-cell lymphoma. Furthermore, the relationship between the exposure level of Keynatinib and its efficacy and safety, the penetration rate of keynatinib in the Blood-Brain Barrier (BBB) and its PK characteristics in cerebrospinal fluid in R/R-PCNSL patients, the relationship between the BTK receptor occupancy rate and the efficacy are also evaluated.

Conditions

  • Lymphoma, B-Cell

Interventions

  • KeynatinibDrug

    All subjects shall be treated with Keynatinib twice a day (once every 12 hours), 20 mg each time, fasting within 2 hours before and 1 hour after taking the drug, and taking warm water when taking the drug. It is recommended to take the drug at the same time every day. In case of missed administration, the subjects should be instructed to take it as soon as possible when they think of it on the same day. If it is within 3 hours later than the scheduled administration, the study drug should be taken as soon as possible; if the interval is \> 3 hours, skip this time and take the next dose at the normal scheduled time. Do not take double dose at one time. Every 28 days is a treatment cycle until the specified interview completed, PD, intolerable toxicity, death occurs or withdraw from the study (including withdrawal of informed consent by the subject or termination of the study when the investigator judges that the risk is greater than the benefit), whichever occurs first.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (CR+PR)Time frame: Every 2 administration cycles in cycle 1-6 and every 3 administration cycles in cycle 7-n.

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

  • West China Hospital,Sichuan University

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.